Business Wire

DeepCure to Present In Vivo Efficacy and Safety Data of BRD4 (BD2) Inhibitor DC-9476 for Macrophage Activation Syndrome at EMBO Conference

BOSTON--(BUSINESS WIRE)--DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, today announced it will present early safety and efficacy data for ...
Business Wire

DeepCure to Present First Ex Vivo Rheumatoid Arthritis Patient Data for Selective BRD4 (BD2) Inhibitor DC-9476 at ACR Convergence 2024

BOSTON--(BUSINESS WIRE)--DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, will present new in vivo data demonstrating its selective BRD4 (BD2) ...